Skip to main content
. Author manuscript; available in PMC: 2019 Jan 17.
Published in final edited form as: ACS Chem Neurosci. 2017 Nov 7;9(1):51–72. doi: 10.1021/acschemneuro.7b00271

Figure 2.

Figure 2

In the presence of activating ligands and absence of inhibitory ligands on the target cell, NK cells are activated to release cytotoxic effectors and cytokines. Coating cancer cells with sialylated glycopolymers by membrane insertion can emulate cancer associated glycosylation changes that engage the Siglec family of inhibitory receptors. Localization of Siglecs to the site of activation enhances SHP-1/2 phosphatase recruitment to halt the phosphorylation cascade before cellular activation. Reprinted from109, with permission.